TEVA PHARMACEUTICAL INDUSTRIES LTD Form 6-K May 20, 2003

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

Teva Pharmaceutical Industries Limited
(Translation of registrant's name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 49131 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F <u>X</u> Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby Furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes NoX

If "Yes" is marked, in 82	indicate below the file number assigned to the registrant in connection with Rule 12g(
		(2)		

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K
May 20, 2003
NOTICE
At the Annual General Meeting of Shareholders of Teva Pharmaceutical Industries Ltd. which took place on May 19, 2003, the following resolutions were adopted:
(i) Resolutions 1-6 on the Agenda were adopted by a simple majority of those in attendance at the General Meeting
In addition, at the Board of Directors meeting that was held after the Annual General Meeting, Mr. E. Hurvitz was nominated as the Chairman of the Board for a period of
3 years.

Teva Pharmaceutical Industries Ltd.



____(3)____

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report	to be
signed on its behalf by the undersigned, thereunto duly authorized.	

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Dan Suesskind

Name: Dan Suesskind

Title: Chief Financial Officer

Date: May 20, 2003

____(4)____